Artis BioSolutions Acquires Landmark Bio

Repligen Corporation Acquires ARTeSYN Biosolutions for $200M

October 28, 2020

Medical Devices

Repligen Corporation has agreed to acquire privately-held ARTeSYN Biosolutions for approximately $200 million (about $130 million cash and $70 million in Repligen stock). The purchase expands Repligen's single-use downstream bioprocessing systems portfolio — ARTeSYN was projected to generate roughly $30 million in pro forma 2020 revenue and the deal complements Repligen's recent EMT and NMS acquisitions.

Cerberus Capital Management Acquires Landmark Structures from Graycliff Partners

December 20, 2024

Infrastructure

Cerberus Capital Management has acquired Landmark Structures, a North American designer, manufacturer and installer of elevated water and industrial storage tanks, from Graycliff Partners. Landmark, headquartered in Texas, will continue to be led by CEO Chris Lamon (who and the management team retain a minority stake) and will receive Cerberus' support to expand capabilities, services and geographic reach.

CellBio Scientific Acquires BioChain

May 1, 2025

Biotechnology

CellBio Scientific, a provider of life science tools and research services, has acquired BioChain, a biospecimen collection, preparation, and analysis company based in Newark, California. The acquisition expands CellBio Scientific's capabilities in spatial genomics and biospecimen workflows, consolidating BioChain with System Biosciences and Acepix Biosciences to create a broader translational research platform.

Select Medical Acquires Landmark Hospital of Savannah

December 9, 2025

Healthcare Services

Select Medical Corporation has acquired Landmark Hospital of Savannah, a 50‑bed long‑term acute care hospital in Savannah, Georgia, from Landmark Holdings of Florida. Select Medical relocated its Select Specialty Hospital – Savannah operations (previously a 40‑bed facility) into the newly acquired hospital to expand its post‑ICU and critical‑illness recovery services in the market.

Landmark Aquatic Acquires CEM Aquatics

January 7, 2026

Construction

Landmark Aquatic has acquired CEM Aquatics, a Salt Lake City–based commercial aquatics design, build, renovation, and maintenance firm with more than four decades of experience. Founder Craig Nielsen and the CEM leadership team will remain in place as integration begins, with Landmark saying the deal expands its capabilities and service footprint in the aquatics sector.

AbbVie Acquires Landos Biopharma

May 23, 2024

Biotechnology

AbbVie has completed the acquisition of clinical-stage biopharmaceutical company Landos Biopharma, adding Landos’ lead investigational asset NX-13 — an oral NLRX1 agonist in Phase 2 for ulcerative colitis — to AbbVie’s immunology pipeline. The deal was valued at $20.42 per share plus contingent value rights tied to a clinical milestone and will take Landos private, with Landos common stock ceasing NASDAQ trading prior to May 24, 2024.